Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in branch ducts are thought to be less aggressive than their main-duct counterparts, and guidelines for their conservative management were recently proposed. This study describes the combined experience of 2 tertiary centers with branch-duct IPMNs aiming to validate these recommendations.A review of 145 patients with resected, pathologically confirmed, branch-duct IPMNs between 1990 and 2005 was conducted.Sixty-six patients (45.5\%) had adenoma, 47 (32\%) borderline tumors, 16 (11\%) carcinoma in situ, and 16 (11\%) invasive carcinoma. Median age was similar between benign and malignant subgroups (66 vs 67.5 years, respectively). Jaundice was more frequent in patients with cancer (12.5\% vs 1.8\%, respectively, P = .022) and abdominal pain in patients with benign tumors (45\% vs 25\%, respectively, P = .025). Forty percent of tumors were discovered incidentally. Findings associated with malignancy were the presence of a thick wall (P < .001), nodules (P < .001), and tumor diameter >or=30 mm (P < .001). All neoplasms with cancer were larger than 30 mm in size or had nodules or caused symptoms. After a mean follow-up of 45 months, the 5-year disease-specific survival for branch-duct IPMNs with noninvasive neoplasms was 100\% and, for invasive cancer, was 63\%.This large cohort of resected branch-duct IPMNs shows that cancer is present in 22\% of cases and validates the recent guidelines that indicate absence of malignancy in tumors <30 mm, without symptoms or mural nodules.

Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection.

SALVIA, Roberto;CRIPPA, Stefano;BASSI, Claudio;FALCONI, Massimo;Capelli, Paola;PEDERZOLI, Paolo;
2007-01-01

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in branch ducts are thought to be less aggressive than their main-duct counterparts, and guidelines for their conservative management were recently proposed. This study describes the combined experience of 2 tertiary centers with branch-duct IPMNs aiming to validate these recommendations.A review of 145 patients with resected, pathologically confirmed, branch-duct IPMNs between 1990 and 2005 was conducted.Sixty-six patients (45.5\%) had adenoma, 47 (32\%) borderline tumors, 16 (11\%) carcinoma in situ, and 16 (11\%) invasive carcinoma. Median age was similar between benign and malignant subgroups (66 vs 67.5 years, respectively). Jaundice was more frequent in patients with cancer (12.5\% vs 1.8\%, respectively, P = .022) and abdominal pain in patients with benign tumors (45\% vs 25\%, respectively, P = .025). Forty percent of tumors were discovered incidentally. Findings associated with malignancy were the presence of a thick wall (P < .001), nodules (P < .001), and tumor diameter >or=30 mm (P < .001). All neoplasms with cancer were larger than 30 mm in size or had nodules or caused symptoms. After a mean follow-up of 45 months, the 5-year disease-specific survival for branch-duct IPMNs with noninvasive neoplasms was 100\% and, for invasive cancer, was 63\%.This large cohort of resected branch-duct IPMNs shows that cancer is present in 22\% of cases and validates the recent guidelines that indicate absence of malignancy in tumors <30 mm, without symptoms or mural nodules.
Adenocarcinoma; Mucinous; Adenoma; Adult; Aged; 80 and over; Carcinoma in Situ; Carcinoma; Pancreatic Ductal; Papillary; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence; Local; Pancreatic Neoplasms; Postoperative Complications; Practice Guidelines as Topic; Survival Analysis
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/353374
Citazioni
  • ???jsp.display-item.citation.pmc??? 83
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact